Skip to main content

Keytruda Disease Interactions

There are 9 disease interactions with Keytruda (pembrolizumab).

Major

Pembrolizumab (applies to Keytruda) immune system disorder

Major Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder

Pembrolizumab can cause immune-mediated adverse reactions, which may be severe or fatal. Immune-mediated adverse reactions can occur in any organ system or tissue, can affect more than 1 body system simultaneously, and can occur at any time after starting therapy. Care should be exercised when using pembrolizumab in patients with preexisting immune system disorders (e.g., ulcerative colitis, Crohn's disease, lupus) or with conditions affecting the nervous system (e.g., myasthenia gravis, Guillain-Barre syndrome). It is recommended to monitor patients closely for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Liver enzymes, creatinine, and thyroid function should be evaluated at baseline and periodically during therapy. For patients with triple-negative breast cancer treated with pembrolizumab in the neoadjuvant setting, blood cortisol should be monitored at baseline, before surgery, and as clinically indicated. If immune-mediated adverse reactions are suspected, appropriate workup should be started to exclude alternative etiologies (including infection). Medical management should be started promptly, including specialty consultation as appropriate. Pembrolizumab should be withheld or permanently discontinued depending on severity.

Switch to professional interaction data

Moderate

PD-1/PD-L1 inhibitors (applies to Keytruda) HSCT

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Transplantation

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.

Switch to professional interaction data

Moderate

PD-1/PD-L1 inhibitors (applies to Keytruda) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

Myasthenic syndrome/myasthenia gravis (including exacerbation) has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients with myasthenia gravis.

Switch to professional interaction data

Moderate

PD-1/PD-L1 inhibitors (applies to Keytruda) organ transplant

Moderate Potential Hazard, Moderate plausibility.

Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.

Switch to professional interaction data

Moderate

Pembrolizumab (applies to Keytruda) colitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Inflammatory Bowel Disease, Infectious Diarrhea/Enterocolitis/Gastroenteritis

Pembrolizumab can cause immune-mediated colitis, which may present with diarrhea. CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to exclude alternative etiologies. Pembrolizumab should be withheld or permanently discontinued depending on severity of colitis.

Switch to professional interaction data

Moderate

Pembrolizumab (applies to Keytruda) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Pembrolizumab can cause immune-mediated hepatitis. Pembrolizumab in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of grades 3 and 4 ALT and AST elevations compared to pembrolizumab alone. Liver enzymes should be monitored before starting and periodically during therapy; more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents should be considered. Pembrolizumab should be withheld or permanently discontinued depending on severity of hepatitis.

Mild liver dysfunction (total bilirubin up to the upper limit of normal [ULN] and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN and any AST) had no clinically significant effect on the clearance of pembrolizumab. The effect of moderate or severe liver dysfunction on the pharmacokinetics of pembrolizumab is unknown. Care should be exercised when using pembrolizumab in patients with liver dysfunction.

Switch to professional interaction data

Moderate

Pembrolizumab (applies to Keytruda) multiple myeloma

Moderate Potential Hazard, Moderate plausibility.

The use of pembrolizumab in combination with a thalidomide analog plus dexamethasone is not recommended in patients with multiple myeloma outside of controlled trials. In 2 randomized trials in patients with multiple myeloma, the addition of pembrolizumab to a thalidomide analog plus dexamethasone, a use for which no programmed death receptor-1 or programmed death ligand-1 (PD-1 or PD-L1) blocking antibody is indicated, resulted in increased mortality.

Switch to professional interaction data

Moderate

Pembrolizumab (applies to Keytruda) pneumonitis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment, History - Radiation Therapy

Pembrolizumab can cause immune-mediated pneumonitis; fatal cases have been reported. In general, the incidence of pneumonitis was higher in patients with prior thoracic radiation. Care should be exercised when using pembrolizumab in patients with preexisting pulmonary impairment and in those who have received thoracic radiation. Pembrolizumab should be withheld or permanently discontinued depending on severity of pneumonitis.

Switch to professional interaction data

Moderate

Pembrolizumab (applies to Keytruda) thyroid disease

Moderate Potential Hazard, Moderate plausibility.

Pembrolizumab can cause immune-mediated thyroid disorders. Thyroid function should be evaluated at baseline and periodically during therapy. It is recommended to initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Pembrolizumab should be withheld or permanently discontinued depending on severity. Care should be exercised when using pembrolizumab in patients with thyroid disease.

Switch to professional interaction data

Keytruda drug interactions

There are 402 drug interactions with Keytruda (pembrolizumab).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.